If TG2 inhibitors (small molecule or antibody) are not specific, potential off-target TG inhibition effects can occur, such as parakeratosis from inhibition of TG1, 3, and 5 [46], bleeding disorders following inhibition of Factor XIIIa [6], and neuron disorders relating to TG6. Here, F13A1 is linked to hemorrhagic disease.